Dapagliflozin in Active Lupus Nephritis

Lupus nephritis is a chronic and life-threatening autoimmune cause of kidney disease that predominately impacts young people and can lead to kidney failure. Sodium-glucose co-transporter-2 inhibitors, including dapagliflozin, are known to improve outcomes for people with other causes of chronic kidney disease. This pilot and feasibility randomized clinical trial will test the use of dapagliflozin versus placebo in addition to standard of care treatment for patients with early and active lupus nephritis, a group who has not been included in past trials.

NCT Number	NCT07323524
Lead Sponsor	Brigham and Women's Hospital Collaborators: Massachusetts General Hospital
Conditions	Lupus Nephritis (LN)
Enrollment	33 participants
Start Date	2026-05-19
Primary Completion	2029-07 (estimated)
Study Completion	2030-01 (estimated)
Updated on ClinicalTrials.gov	2026-05-26